Table 3.
Baseline CXR feature | Number of cases | % |
---|---|---|
Pattern | ||
Normal | 8 | 14% |
GGO | 31 | 56% |
Consolidation | 4 | 7% |
Mixed | 13 | 23% |
CoV-P category | ||
CoV-P1 | 27 | 48% |
CoV-P2 | 29 | 52% |
Lung involvement among CXRs with positive findings (48) | ||
Unilateral | 8 | 14% |
Bilateral | 48 | 86% |
Vertical distribution among CXRs with positive findings (48) | ||
Lower predominant | 50 | 89% |
Upper predominant | 0 | 0% |
Diffuse involvement | 6 | 11% |
Transverse distribution among CXRs with positive findings (48) | ||
Peripheral | 6 | 11% |
Perihilar | 0 | 0% |
No predilection | 50 | 89% |
(GGO = Ground Glass Opacities).